Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Other Non-Current Liabilities (2016 - 2025)

Lisata Therapeutics filings provide 13 years of Other Non-Current Liabilities readings, the most recent being $72000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Liabilities changed 0.0% year-over-year to $72000.0, compared with a TTM value of $72000.0 through Dec 2025, changed 0.0%, and an annual FY2025 reading of $72000.0, changed 0.0% over the prior year.
  • Other Non-Current Liabilities hit $72000.0 in Q4 2025 for Lisata Therapeutics, roughly flat from $72000.0 in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $337000.0 in Q1 2023, with the low at $72000.0 in Q3 2024.
  • Median Other Non-Current Liabilities over the past 3 years was $95500.0 (2024), compared with a mean of $150833.3.
  • The sharpest move saw Other Non-Current Liabilities tumbled 71.54% in 2024, then changed 0.0% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $210000.0 in 2023, then crashed by 65.71% to $72000.0 in 2024, then changed by 0.0% to $72000.0 in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $72000.0, $72000.0, and $72000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.